Catalent (NYSE:CTLT) Issues Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Catalent (NYSE:CTLT) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis.

Catalent Stock Performance

CTLT stock traded up $1.41 during mid-day trading on Wednesday, reaching $59.89. 2,784,774 shares of the stock traded hands, compared to its average volume of 2,042,626. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The business has a 50-day moving average of $60.03 and a two-hundred day moving average of $58.02. The firm has a market capitalization of $10.87 billion, a PE ratio of -10.65, a P/E/G ratio of 2.06 and a beta of 1.16. Catalent has a 52 week low of $32.38 and a 52 week high of $61.20.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com began coverage on shares of Catalent in a research note on Saturday, October 12th. They set a “hold” rating on the stock. Nine equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $59.83.

Insider Buying and Selling

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.